N/A N=12 Facilitating Engagement in Evidence-Based Treatment for Early Psychosis
Psychotic Disorders
Primary: Change in Decisional Conflict Scale — 0.55 score on a scale — p=.95
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,214 CardioMEMS HF System Post Approval Study
Heart Failure · Left-Sided Heart Failure · Congestive Heart Failure
Primary: Freedom From Device and/or System Related Complication (DSRC) — 1209 Participants — p=<0.0001
Phase 3 N=100 The Effect of Guanfacine on Delirium in Critically Ill Patients
Delirium
Primary: Days Without Delirium — 2.54; 3.38 delirium free days — p=0.22
N/A N=112 The Effect of Reducing Posttraumatic Stress Disorder Symptoms on Cardiovascular Risk
PTSD
Primary: Change From Baseline to Post-Intervention in 24-hour Heart Rate Variability (HRV) Estimated From the Standard Deviation of the Interbeat Interval of Normal Sinus Beats…
N/A N=19 Post-Prandial Liver Glucose Metabolism in PCOS
Polycystic Ovarian Syndrome · Obesity · Hepatic Steatosis
Primary: Hepatic Fat Fraction — 8.35 Percent
N/A N=235 Virtual Diabetes Specialty Clinic: A Study Evaluating Remote Initiation of Continuous Glucose Monitoring
Type 1 Diabetes · Type 2 Diabetes
Primary: Hemoglobin A1C (HbA1c) — 54 mmol/mol
Phase 2 N=202 Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
Psoriasis · Skin Diseases
Primary: Percent Change From Baseline in Psoriasis Activity and Severity Index (PASI) Score at Week 16 — -17.30; -52.60; -61.20; -63.70 percent change — p=<0.001
Phase 2 N=30 Naloxone, Hypoglycemia and Exercise
Diabetes Mellitus, Type 1
Primary: Change in Symptom Score — 25; 21 score on a scale
N/A N=17 Impact of Prisma on Donor Site Pain
Skin Graft Disorder · Donor Site Complication
Primary: Pain Score on Visual Analogue Scale (VAS) — 2; 2 score on a scale
N/A N=18 Ultrasound Efficacy in Moderate Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Low Synovitis Scores — 1 Participants
Phase 2 N=207 Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
Pneumococcal Vaccines
Primary: Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination — 42.3; 62.7; 37.7; 48.0 percentage of participants
Phase 4 N=50 Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
Psoriasis
Primary: Psoriasis Area Severity Index 75 at Week 12 — 29 Participants
N/A N=30 Glycemic Optimization On Discharge From the Emergency Room
Diabetes Mellitus
Primary: Change in Diabetes Distress — 0; 0.5 units on a scale
N/A N=60 Producing a Fully Asynchronous Online Savvy Program
Dementia
Primary: Center for Epidemiologic Studies - Depression (CES-D) Score — 11.483; 9.345; 8.964; 14.317 score on a scale
N/A N=30 Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
Lymphoma · Plasma Cell Myeloma
Primary: Fidelity to Intervention Delivery — 19.9 score on a scale